De-risking prostate cancer screening with ClarityDX Prostate
ClarityDX Prostate builds upon the utility of clinical features and blood-based biomarkers to determine a patient’s risk of having aggressive prostate cancer. This empowers patients and their healthcare providers make more informed healthcare decisions.
Dr. John Lewis
CEO of Nanostics and Bird Dogs Chair of Translational Oncology at the University of Alberta
Recent News
Dr. John Lewis Speaks on “How can I protect myself from prostate cancer?” on CBC Podcast The Dose
Listen as Dr. John Lewis speaks on the CBC's [...]
Sean Secord Speaks on Prostate Cancer Screening at PROSTAID
Sean Secord had the opportunity to speak at PROSTAID's [...]
Nanostics Gets Featured on New Podcast by AIMSS
Nanostics was excited to be the first to be [...]